Clinical Trials
23 trialsNCT07538258 2026-04-20
Aurora004
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Not yet recruiting
NCT07538271 2026-04-20
Aurora 005
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Not yet recruiting
NCT07501169 2026-04-13
STAR-01
Sichuan University
Phase 2 Not yet recruiting
NCT04660097 2026-04-08
Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
Henan Cancer Hospital
Phase 2 Completed
NCT07388875 2026-02-05
SKB264-ANLO
China Medical University, China
Phase 2 Not yet recruiting
NCT07376499 2026-01-29
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
China Medical University, China
Phase 2 Not yet recruiting
NCT07358676 2026-01-22
A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT05001971 2026-01-15
Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy
Hunan Cancer Hospital
Phase 2 Completed
NCT06258642 2025-08-20
Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC
Fudan University
Phase NA Recruiting
NCT06951841 2025-04-30
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
China Medical University, China
Phase 4 Not yet recruiting
NCT06931145 2025-04-23
Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
Peking Union Medical College Hospital
Phase 4 Not yet recruiting
NCT04165330 2025-02-24
Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors
Sarcoma Oncology Research Center, LLC
Phase 1/2 Active not recruiting
NCT04985851 2023-12-01
To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.
Shanghai Chest Hospital
Phase NA Unknown
NCT04731909 2021-02-10
Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer
Third Military Medical University
Phase NA Unknown
NCT04620837 2020-11-09
Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy
ChineseAMS
Phase 2 Unknown
NCT04363255 2020-04-28
First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC
Taizhou Hospital
Phase 2 Unknown
NCT04314297 2020-03-19
Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT03700359 2019-11-29
A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC
The First Affiliated Hospital of Guangzhou Medical University
Phase 2 Unknown
NCT04073550 2019-08-29
Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Unknown
NCT03059797 2019-05-16
Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Completed
NCT03841136 2019-03-28
Anlotinib Combined With Etoposide and Platinum in the Treatment of Lung Cancer
Fudan University
Phase 2 Unknown
NCT03780283 2018-12-21
Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC
First Hospital of Shijiazhuang City
Phase 2 Unknown
NCT03732846 2018-11-07
Anlotinib in Treatment of Recurrent Small Cell Lung Cancer
Peking University Cancer Hospital & Institute
Phase 2 Unknown